elanco animal health inc. - ELAN
ELAN
Close Chg Chg %
21.70 0.51 2.35%
Open Market
22.21
+0.51 (2.35%)
Volume: 2.93M
Last Updated:
Dec 16, 2025, 1:18 PM EDT
Company Overview: elanco animal health inc. - ELAN
ELAN Key Data
| Open $22.40 | Day Range 21.77 - 22.53 |
| 52 Week Range 8.02 - 23.66 | Market Cap $10.78B |
| Shares Outstanding 496.86M | Public Float 492.27M |
| Beta 1.86 | Rev. Per Employee N/A |
| P/E Ratio 292.04 | EPS $0.07 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 5.13M |
ELAN Performance
| 1 Week | 1.93% | ||
| 1 Month | 2.89% | ||
| 3 Months | 13.02% | ||
| 1 Year | 86.59% | ||
| 5 Years | -27.69% |
ELAN Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
18
Full Ratings ➔
About elanco animal health inc. - ELAN
Elanco Animal Health, Inc. develops, manufactures, and markets products for pets and farm animals. Its products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, TruCan, AviPro, Baytril, Catosal, Denagard, and Experior. The company was founded in 1954 and is headquartered in Indianapolis, IN.
ELAN At a Glance
Elanco Animal Health, Inc.
450 Elanco Circle
Indianapolis, Indiana 46221
| Phone | 1-877-352-6261 | Revenue | 4.44B | |
| Industry | Biotechnology | Net Income | 338.00M | |
| Sector | Health Technology | 2024 Sales Growth | 0.498% | |
| Fiscal Year-end | 12 / 2025 | Employees | 9,450 | |
| View SEC Filings |
ELAN Valuation
| P/E Current | 292.044 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 17.817 |
| Price to Sales Ratio | 1.357 |
| Price to Book Ratio | 0.982 |
| Price to Cash Flow Ratio | 11.13 |
| Enterprise Value to EBITDA | 10.951 |
| Enterprise Value to Sales | 2.252 |
| Total Debt to Enterprise Value | 0.444 |
ELAN Efficiency
| Revenue/Employee | 469,735.45 |
| Income Per Employee | 35,767.196 |
| Receivables Turnover | 4.408 |
| Total Asset Turnover | 0.329 |
ELAN Liquidity
| Current Ratio | 2.445 |
| Quick Ratio | 1.248 |
| Cash Ratio | 0.356 |
ELAN Profitability
| Gross Margin | 43.005 |
| Operating Margin | 5.654 |
| Pretax Margin | 10.993 |
| Net Margin | 7.614 |
| Return on Assets | 2.506 |
| Return on Equity | 5.487 |
| Return on Total Capital | 3.207 |
| Return on Invested Capital | 3.00 |
ELAN Capital Structure
| Total Debt to Total Equity | 72.90 |
| Total Debt to Total Capital | 42.163 |
| Total Debt to Total Assets | 35.231 |
| Long-Term Debt to Equity | 71.67 |
| Long-Term Debt to Total Capital | 41.452 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Elanco Animal Health Inc. - ELAN
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 4.76B | 4.41B | 4.42B | 4.44B | |
Sales Growth
| +45.57% | -7.43% | +0.14% | +0.50% | |
Cost of Goods Sold (COGS) incl D&A
| 2.69B | 2.44B | 2.48B | 2.53B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 716.00M | 682.00M | 694.00M | 662.00M | |
Depreciation
| 160.00M | 89.00M | 92.00M | 95.00M | |
Amortization of Intangibles
| 556.00M | 593.00M | 602.00M | 567.00M | |
COGS Growth
| +32.74% | -9.26% | +1.56% | +2.06% | |
Gross Income
| 2.08B | 1.97B | 1.94B | 1.91B | |
Gross Income Growth
| +66.43% | -5.06% | -1.62% | -1.50% | |
Gross Profit Margin
| +43.55% | +44.66% | +43.88% | +43.01% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.77B | 1.59B | 1.61B | 1.66B | |
Research & Development
| 369.00M | 321.00M | 327.00M | 344.00M | |
Other SG&A
| 1.40B | 1.26B | 1.28B | 1.31B | |
SGA Growth
| +33.95% | -10.55% | +1.64% | +2.85% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 673.00M | 188.00M | 1.16B | 172.00M | |
EBIT after Unusual Expense
| (371.00M) | 196.00M | (836.00M) | 79.00M | |
Non Operating Income/Expense
| 68.00M | (12.00M) | (82.00M) | 748.00M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 264.00M | 256.00M | 277.00M | 339.00M | |
Interest Expense Growth
| +69.23% | -3.03% | +8.20% | +22.38% | |
Gross Interest Expense
| 264.00M | 256.00M | 277.00M | 339.00M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (567.00M) | (72.00M) | (1.20B) | 488.00M | |
Pretax Income Growth
| +15.63% | +87.30% | -1,559.72% | +140.84% | |
Pretax Margin
| -11.90% | -1.63% | -27.05% | +10.99% | |
Income Tax
| (95.00M) | 6.00M | 36.00M | 150.00M | |
Income Tax - Current - Domestic
| 1.00M | 12.00M | (6.00M) | (12.00M) | |
Income Tax - Current - Foreign
| 58.00M | 51.00M | 122.00M | 274.00M | |
Income Tax - Deferred - Domestic
| (10.00M) | (21.00M) | (14.00M) | 2.00M | |
Income Tax - Deferred - Foreign
| (144.00M) | (36.00M) | (66.00M) | (114.00M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (472.00M) | (78.00M) | (1.23B) | 338.00M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (472.00M) | (78.00M) | (1.23B) | 338.00M | |
Net Income Growth
| +15.73% | +83.47% | -1,478.21% | +127.46% | |
Net Margin Growth
| -9.91% | -1.77% | -27.87% | +7.61% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (472.00M) | (78.00M) | (1.23B) | 338.00M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (472.00M) | (78.00M) | (1.23B) | 338.00M | |
EPS (Basic)
| -0.9688 | -0.1597 | -2.5005 | 0.6842 | |
EPS (Basic) Growth
| +23.65% | +83.52% | -1,465.75% | +127.36% | |
Basic Shares Outstanding
| 487.20M | 488.30M | 492.30M | 494.00M | |
EPS (Diluted)
| -0.9688 | -0.1597 | -2.5005 | 0.6797 | |
EPS (Diluted) Growth
| +23.65% | +83.52% | -1,465.75% | +127.18% | |
Diluted Shares Outstanding
| 487.20M | 488.30M | 492.30M | 497.30M | |
EBITDA
| 1.02B | 1.07B | 1.02B | 913.00M | |
EBITDA Growth
| +131.31% | +4.72% | -4.32% | -10.49% | |
EBITDA Margin
| +21.36% | +24.17% | +23.09% | +20.57% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 25.154 | |
| Number of Ratings | 18 | Current Quarters Estimate | 0.113 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | 0.933 | |
| Last Quarter’s Earnings | 0.19 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.91 | Next Fiscal Year Estimate | 1.035 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 15 | 12 | 16 | 16 |
| Mean Estimate | 0.11 | 0.35 | 0.93 | 1.04 |
| High Estimates | 0.16 | 0.39 | 0.98 | 1.12 |
| Low Estimate | 0.10 | 0.30 | 0.92 | 0.99 |
| Coefficient of Variance | 12.65 | 5.95 | 1.49 | 3.20 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 9 |
| OVERWEIGHT | 1 | 0 | 0 |
| HOLD | 3 | 3 | 6 |
| UNDERWEIGHT | 1 | 1 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Elanco Animal Health Inc. - ELAN
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Elanco Animal Health Inc. - ELAN
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 20, 2025 | Jeffrey N. Simmons PRESIDENT, CEO AND DIRECTOR; Director | 18,356 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 20, 2025 | Rajeev Modi SEE REMARKS | 7,230 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Apr 8, 2025 | Timothy Bettington SEE REMARKS | 110,262 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $9.72 per share | 1,071,746.64 |
| Mar 12, 2025 | Lawrence Erik Kurzius Director | 111,459 | Open market or private purchase of non-derivative security Non-derivative transaction at $10.2 per share | 1,136,881.80 |
| Mar 12, 2025 | Lawrence Erik Kurzius Director | 101,459 | Open market or private purchase of non-derivative security Non-derivative transaction at $10.9 per share | 1,105,903.10 |
| Mar 12, 2025 | José Manuel Correia de Simas SEE REMARKS | 4,643 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | José Manuel Correia de Simas SEE REMARKS | 46,383 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | José Manuel Correia de Simas SEE REMARKS | 1,830 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | James M. Meer CHIEF ACCOUNTING OFFICER | 59,264 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Ramiro M. Cabral SEE REMARKS | 92,765 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Ramiro M. Cabral SEE REMARKS | 239,629 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | David S. Kinard SEE REMARKS | 46,383 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | David S. Kinard SEE REMARKS | 188,878 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Todd S. Young SEE REMARKS | 134,509 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Todd S. Young SEE REMARKS | 200,969 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Timothy Bettington SEE REMARKS | 64,936 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Ellen de Brabander SEE REMARKS | 106,123 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Ellen de Brabander SEE REMARKS | 221,740 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Jeffrey N. Simmons PRESIDENT, CEO AND DIRECTOR; Director | 14,891 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 6, 2025 | Jeffrey N. Simmons PRESIDENT, CEO AND DIRECTOR; Director | 556,587 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |